Promising clinical trials in front- & second-line therapy for advanced metastatic pancreatic cancer

FAQ Library published on November 6, 2017
Download Transcript Download Audio
Ramesh K. Ramanathan, MD
Director, GI Medical Oncology
Vice Chair of Research
Division of Hematology/Oncology
Mayo Clinic
Phoenix, Arizona
Promising clinical trials in front- & second-line therapy for advanced metastatic pancreatic cancer

Welcome to Partners in Pancreatic Cancer. I am Dr. Ramesh Ramanathan from the Mayo Clinic in Phoenix, Arizona. I am frequently asked, “What are some of the most promising clinical trials we should be keeping an eye on in the front-line and second-line therapy for advanced pancreatic cancer?”

There are a number of promising agents in clinical trials. One of the studies that I am involved with is pegylated PH20 with the pegylated hyaluronidase. This is in a phase 3 registration study sponsored by Halozyme in combination with gemcitabine and nab-paclitaxel. An interesting aspect of this study is that it is only for hyaluronan-high tumors. We expect about 40% of front-line patients will have high hyaluronan levels by immunohistochemistry, and these patients are randomized to gemcitabine-nab-paclitaxel with or without PEGPH20.

Another clinical trial is a SWOG study with FOLFIRINOX in combination with PEGPH20 which was closed at interim analysis. This was in unselected patients where PEGPH20 did not show a benefit. This is something to keep an eye on.

Another agent which is nearing completion of a phase 3 study is ibrutinib. This is also in front-line with gemcitabine and nab paclitaxel, and hopefully, we will be seeing the results of this study in 2018 or 2019.

Another agent is a stem cell factor called BBI-608. This is in front-line studies with gemcitabine and nab-paclitaxel and also a second-line study with 5-FU and MM-398. Everyone is very interested in immuno-oncology studies and there are a number of studies, probably 30 to 40 studies. These are still phase 1 and phase 2 in the first-, second-line and refractory settings with a number of immuno oncology agents and co-stimulatory molecules. These would be very interesting as proof of concept. If these are active, we will see these moving to randomized studies. Thank you for viewing this activity.

Last modified: July 24, 2017
Related Items by Author
Where does oxaliplatin fit in the treatment paradigm for advanced metastatic pancreatic cancer?
Ramesh K. Ramanathan, MD
FAQ Library published on September 11, 2017
Will immunotherapy have a future role in advanced pancreatic cancer?
Ramesh K. Ramanathan, MD
FAQ Library published on July 10, 2017

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2018 MediCom Worldwide, Inc. All rights reserved